2024
Outcomes following total shoulder arthroplasty in patients with systemic lupus erythematosus
Salib A, Sanchez J, Huggins L, Seddio A, Dhodapkar M, Smith-Voudouris J, Norman M, Koumpouras F, Grauer J. Outcomes following total shoulder arthroplasty in patients with systemic lupus erythematosus. Journal Of Shoulder And Elbow Surgery 2024 PMID: 39154846, DOI: 10.1016/j.jse.2024.07.008.Peer-Reviewed Original ResearchSystemic lupus erythematosus patientsSystemic lupus erythematosusTotal shoulder arthroplastyAdverse eventsImplant survivalLupus erythematosusMultivariate analysisShoulder arthroplastyIncreased oddsTotal shoulder arthroplasty patientsNon-SLE patientsMultivariate logistic regressionImmunomodulatory therapyPostoperative complicationsElixhauser Comorbidity IndexAdult patientsNinety-dayUnivariate analysisSurgical planningComorbidity indexPatient counselingGlenohumeral osteoarthritisPatientsComorbid conditionsOrthopedic-relatedA dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
Stabach P, Sims D, Gomez-Bañuelos E, Zehentmeier S, Dammen-Brower K, Bernhisel A, Kujawski S, Lopez S, Petri M, Goldman D, Lester E, Le Q, Ishaq T, Kim H, Srivastava S, Kumar D, Pereira J, Yarema K, Koumpouras F, Andrade F, Braddock D. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. JCI Insight 2024, 9: e177003. PMID: 38888971, PMCID: PMC11383374, DOI: 10.1172/jci.insight.177003.Peer-Reviewed Original ResearchSystemic lupus erythematosusDNASE1L3 deficiencySporadic systemic lupus erythematosusAssociated with systemic lupus erythematosusChromatin degradationDNA accumulationDevelopment of lupusPristane-induced lupusSelf-DNACell free DNAHuman isoformsSystemic lupus erythematosus plasmasDouble knockout miceDNASE1L3Pathogenic effectsFree DNALupus modelEnzymeInducible lupus modelAdult patientsLupus erythematosusKnockout micePediatric populationAutoimmune diseasesDNA
2023
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial
Merrill J, Guthridge J, Smith M, June J, Koumpouras F, Machua W, Askanase A, Khosroshahi A, Sheikh S, Rathi G, Burington B, Foster P, Matijevic M, Arora S, Wang X, Gao M, Wax S, James J, Zack D. Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial. Arthritis & Rheumatology 2023, 75: 2185-2194. PMID: 37459248, DOI: 10.1002/art.42652.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusLoss of improvementPrimary endpointLupus erythematosusWeek 32B cellsEfficacy-evaluable populationImproved disease activityPhase 2 trialProportion of patientsTreatment-related toxicityTreatment of patientsPlacebo-ControlledCorticosteroid injectionDisease activityInfusion reactionsTrough concentrationsPatient subsetsPlasma cellsPatientsSecondary analysisMonoclonal antibodiesStatistical significanceEndpointPlaceboVascular-Targeted Therapy for Systemic Lupus Erythematosus–Associated Vasculitis
Xu S, Patrignelli R, Ramachandran S, Koumpouras F, Desir D, Ko C, Gehlhausen J. Vascular-Targeted Therapy for Systemic Lupus Erythematosus–Associated Vasculitis. JAMA Dermatology 2023, 159: 460-462. PMID: 36884229, DOI: 10.1001/jamadermatol.2023.0077.Peer-Reviewed Original Research
2021
Chapter 11 Interferons and cytokines in SLE pathogenesis and therapy
Koumpouras F, Bucala R. Chapter 11 Interferons and cytokines in SLE pathogenesis and therapy. 2021, 169-180. DOI: 10.1016/b978-0-12-820583-9.00015-4.Peer-Reviewed Original Research
2019
FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Merrill J, June J, Koumpouras F, Machua W, Khan M, Askanase A, Khosroshahi A, Sheikh S, James J, Guthridge J, Rathi G, Burington B, Foster P, Zack D. FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). 2019, 761.2-762. DOI: 10.1136/annrheumdis-2019-eular.4234.Peer-Reviewed Original Research98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE)
Merrill J, June J, Koumpouras F, Machua W, Khan M, Askanase A, Sheikh S, Khosroshahi A, Foster P, Zack D. 98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE). 2019, a73-a74. DOI: 10.1136/lupus-2019-lsm.98.Peer-Reviewed Original Research
2015
Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus
Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B. Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology 2015, 67: 1848-1857. PMID: 25777546, PMCID: PMC4732716, DOI: 10.1002/art.39108.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAntibodies, Anti-IdiotypicAntigensCarrier ProteinsCholecalciferolCytoskeletal ProteinsDietary SupplementsDNADose-Response Relationship, DrugDouble-Blind MethodFemaleGene Expression RegulationHumansLupus Erythematosus, SystemicMaleMicroarray AnalysisMiddle AgedMyxovirus Resistance ProteinsProspective StudiesRNA-Binding ProteinsVitamin DConceptsPercentage of patientsVitamin D3Vitamin DIFN signatureTreatment groupsSLE patientsInterferon signatureSystemic lupus erythematosus seraDNA antibody levelsVitamin D repletionPlacebo-controlled trialVitamin D deficientVitamin D supplementationVitamin D3 supplementationSubset of patientsSystemic lupus erythematosusD supplementationD deficientD3 supplementationDisease activityImmunologic outcomesInactive diseaseAdverse eventsBaseline characteristicsLupus erythematosus